It was reported on June 18, that Gary Charles Robb, Chief Business Officer at Corcept Therapeutics CORT executed a significant insider sell, according to an SEC filing.
What Happened: Robb’s recent Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday unveiled the sale of 3,185 shares of Corcept Therapeutics. The total transaction value is $225,402.
The latest market snapshot at Thursday morning reveals Corcept Therapeutics shares down by 0.85%, trading at $71.24.
All You Need to Know About Corcept Therapeutics
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company’s compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders – hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Corcept Therapeutics: A Financial Overview
Revenue Growth: Over the 3 months period, Corcept Therapeutics showcased positive performance, achieving a revenue growth rate of 7.09% as of 31 March, 2025. This reflects a substantial increase in the company’s top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Exploring Profitability:
-
Gross Margin: The company maintains a high gross margin of 98.47%, indicating strong cost management and profitability compared to its peers.
-
Earnings per Share (EPS): Corcept Therapeutics’s EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.19.
Debt Management: Corcept Therapeutics’s debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Insights into Valuation Metrics:
-
Price to Earnings (P/E) Ratio: Corcept Therapeutics’s stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 62.48.
-
Price to Sales (P/S) Ratio: The current P/S ratio of 12.15 is above industry norms, reflecting an elevated valuation for Corcept Therapeutics’s stock and potential overvaluation based on sales performance.
-
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): Corcept Therapeutics’s EV/EBITDA ratio stands at 64.93, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
The Relevance of Insider Transactions
Insider transactions shouldn’t be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an “insider” refers to any officer, director, or beneficial owner of more than ten percent of a company’s equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down.
Unlocking the Meaning of Transaction Codes
Navigating through the landscape of transactions, investors often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Corcept Therapeutics’s Insider Trades.
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don’t miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.